Recipharm forms new collaboration with Isofol Medical to exclusively manufacture Modufolin® and invests SEK 8 million in the company
Recipharm and Isofol Medical AB, a Gothenburg-based pharmaceutical company developing novel products for unmet needs within oncology, are pleased to announce the formation of a collaboration to strengthen the development program of Isofol’s lead drug candidate Modufolin®. At the same time, Recipharm Venture Fund, the life science sector investor with a strategic interest in pharmaceutical …
